Accent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting

Data demonstrate robust and durable anti-cancer activity of ATX-295, a potentially best-in-class KIF18A inhibitor, in multiple preclinical chromosomally instable cancer models LEXINGTON, Mass., April 17, 2026 /PRNewswire/ -- Accent Therapeutics, a clinical-stage biopharmaceutical company...